Sanofi receives FDA approval of Adlyxin TM for treatment of adults with Type 2 Diabetes
28 July 2016 | By Sanofi
U.S. Food and Drug Administration (FDA) have approved Sanofi's Adlyxin TM (lixisenatide), a once-daily mealtime GLP-1 receptor agonist injection indicated as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes...